Arca
Skip to content
Tools
Tools

PIK3CB: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform

Phosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol derivatives at position 3 of the inositol ring to produce 3-phosphoinositides.

  • Drugs that act on it: 5
  • Approved: 0
  • In phases 1 to 3: 5
  • Sponsors: 5

Who is on it, and how far along

Every drug ChEMBL records acting on PIK3CB, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 5

Approved0

    Phase 30

      Phase 22

      • GSK-2636771
      • Fimepinostat

      Phase 13

      • AZD-8186
      • BAY-1082439
      • SAR-260301

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      • Curis, Inc.120%

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: PI3-kinase p110-beta subunit inhibitor.
      GSK-2636771Phase 2GSKSmall moleculeInhibitor3
      FimepinostatPhase 2Curis, Inc.Small moleculeInhibitor1
      AZD-8186Phase 1AstraZeneca PharmaceuticalsSmall moleculeInhibitor0
      BAY-1082439Phase 1BayerSmall moleculeInhibitor0
      SAR-260301Phase 1SanofiSmall moleculeInhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 4 in all, from ClinicalTrials.gov.
      Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing DiseaseFimepinostatPhase 2RecruitingUniversity of California, Los AngelesAug 2, 2023
      Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)GSK-2636771Phase 2Active, not recruitingNational Cancer Institute (NCI)Jun 19, 2020
      Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)GSK-2636771Phase 2Active, not recruitingNational Cancer Institute (NCI)Jun 19, 2020
      Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)GSK-2636771Phase 2Active, not recruitingNational Cancer Institute (NCI)Jun 8, 2015

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Cancer0.58
      • Neurodegenerative disease0.53
      • Alzheimer disease0.48
      • Parkinson disease0.47
      • Lysosomal storage disease0.46
      • Non-small cell lung carcinoma0.46
      • Head and neck squamous cell carcinoma0.40
      • Kidney neoplasm0.38
      • Esophageal adenocarcinoma0.37
      • Lymphoid neoplasm0.37

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3145, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P42338, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.